|
|
|
|
|
|
|
Curriculum Vitae David Lalka, Ph.D. Office Address: Room 2040 (304) 293-1475
EDUCATION State University of New York at Buffalo, B.S./Pharmacy, 1964-1969. State University of New York at Buffalo, Ph.D./Biochemical Pharmacology, 1969-1973. RESEARCH AND PROFESSIONAL EXPERIENCE Undergraduate Research Assistant in Department of Biochemical Pharmacology of State University of New York at Buffalo, 1/67-6/69. Intern in Hospital Pharmacy, Veterans Administration Hospital at Buffalo, 7/69-6/70. Graduate Research Assistant in Department of Biochemical Pharmacology at State University of New York at Buffalo, 6/69-7/73. Senior Research Scientist, Drug Disposition Section, Astra Pharmaceuticals, Worcester, Mass., 7/73-12/74. Head, Drug Disposition Section, Astra Pharmaceuticals, Worcester, Mass., 1/75-10/75. Night Faculty, Northeastern University, School of Pharmacy, Boston, Mass., 9/74-10/75. Assistant Professor of Pharmacology and Pathology, School of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX, 11/75-7/77. Assistant Professor of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, 7/77-6/79. Director, Clinical Pharmacokinetics Laboratory, Buffalo General Hospital, 7/77-9/89. Associate Professor of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, 7/79-11/89. Associate Professor of Biochemical Pharmacology, School of Pharmacy, State University of New York at Buffalo, 9/80-11/89. Research Associate Professor of Surgery, School of Medicine, State University of New York at Buffalo, 9/83-11/89. Douglas Glover Professor of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, 12/89 -11/95. Assistant Dean for Research and Graduate Programs, School of Pharmacy, West Virginia University, 12/84 - 5/95. Professor of Basic Pharmaceutical Sciences, 11/95 - present. COMMITTEE ACTIVITIES 1. Committee on Research Involving Human Subjects, School of Pharmacy, 5/79-9/82 (SUNY/Buffalo). 2. Committee Member, Undergraduate Mathematics and its Applications Project, 1978 (SUNY/Buffalo). 3. Director of Graduate Studies for the Department of Pharmaceutics, 9/81-7/87 (SUNY/Buffalo). 4. Member, Buffalo Pharmaceutics Graduate Scholar Award Selection Committee, 1983-84. 5. Department Representative to the Graduate School Divisional Committee for Health Sciences, 6/81-7/87, (SUNY/Buffalo). 6. Member Search Committee for a Pharmacy Department Chairman, 2/85-3/86 (SUNY/Buffalo). 7. Member School of Pharmacy, Divisional Grievance Committee, 7/86-10/86 (SUNY/Buffalo). 8. Coordinator, Third Annual City-wide Pharmaceutical Sciences Day, 5/8/87 (SUNY/Buffalo). 9. Executive Committee, School of Pharmacy, West Virginia University, 12/89 - 5/94. 10. School of Pharmacy Graduate Affairs and Admissions Committee, 9/90 - 5/94. 11. Chairman Search Committee for Chairperson, Department of Behavioral and Administrative Pharmacy, 6/90 - 1/91. 12. Health Sciences Center Committee on Alleged Misconduct in Research and/or Scholarship, 7/90 - 5/94 (chairman 1/93- 5/94). 13. Search Committee for a Dean for WVU School of Nursing, 8/91 - 5/92. 14. Health Sciences Center Graduate Council, 6/90 - 5/94. 15. Representative for the Health Sciences Center on the University-wide Graduate Council, 9/91 - 5/94. 16. Positron Emission Tomography Internal Advisory Group, 7/91 - 6/93. 17. School of Pharmacy Kellogg Initiative Committee, 9/91 - 5/94. 18. Coordinator for the 12th Annual Undergraduate Research Seminar sponsored by the Merck Foundation, Morgantown, WV, November 13, 1990. 19. Coordinator for the 13th Annual Undergraduate Research Seminar sponsored by the Merck Foundation, Morgantown, WV, October 30, 1991. 20. Search Committee for a Chairperson, Department of Physiology, WVU School of Medicine, 8/92 - 4/93. 21. Chairman, Subcommittee to Evaluate the Ph.D. program in Biology at WVU (9/93 - 4/94) 22. School of Pharmacy Admissions Committee, 9/97-present 23. Department of Basic Pharmaceutical Sciences Promotion and Tenure Committee 9/97-present 24. West Virginia University International Programs Committee, 9/97-present. 25. School of Pharmacy, Academic Standards Committee, 9/97- present. SCIENTIFIC COMMUNITY ACTIVITIES A. Reviewer of Manuscripts for: 1. Journal of Pharmaceutical Sciences 2. Antimicrobial Agents and Chemotherapy 3. International Journal of Pharmaceutics 4. Journal of Pharmacology and Experimental Therapeutics 5. Journal of Pharmacokinetics and Biopharmaceutics 6. Research Communications in Biochemical Pharmacology 7. Drugs 8. Clinical Pharmacokinetics 9. New England Journal of Medicine 10. Journal of Allergy and Clinical Immunology 11. Clinical Pharmacology and Therapeutics 12. Biopharmaceutics and Drug Disposition 13. British Journal of Clinical Pharmacology 14. American Journal of the Medical Sciences 15. Canadian Journal of Physiology and Pharmacology 16. Pharmaceutical Research 17. The FASEB Journal 18. Drug Metabolism and Disposition 19. Journal of the Association of Official Analytical Chemists (JAOACI) 20. British Journal of Pharmacology B. Book Review: 1. Lalka D: Book review of Drug Disposition and Pharmacokinetics by Steven Curry, J Med Chem 18:1168 (1975). 2. Lalka D: Book review of Clinical Pharmacokinetics: Concepts and Applications by Malcolm Rowland and Thomas Tozer, J Pharm Sci 70: 973-974 (1981). C. Grant Reviews Performed for: 1. Medical Research Council of Canada 2. American Heart Association, Texas Affiliate 3. National Institute of General Medical Sciences (ad hoc committees) 4. Veteran's Administration (Merit Review Board) 5. National Cancer Institute (ad hoc contract review committees) D. Academic (Other Universities) Outside Reviewer concerning Retention, Promotion, and Tenure 1. University of Houston 2. University of Kentucky 3. University of Colorado 4. University of Utah 5. University of Pittsburgh 6. University of Connecticut 7. University of Alberta E. Program/Development Grant Review Activities 1. Site visitor for the Medical Research Council of Canada (Development Grant Application) School of Pharmacy, University of Saskatchewan, Saskatoon, Saskatchewan, December 5-6, 1990. 2. Site visitor for the Evaluation of the Graduate Program of Department of Pharmaceutical Sciences, Howard University (12/9/90-12/11/90).
RESEARCH TRAINING A. Visiting Scientists who have worked in my laboratory 1. Roland Heintz, Ph.D.(senior scientist) was sent by and supported by Hoffmann-La Roche-Basle, Switzerland, 8/82 to 4/83. 2. James E. Axelson, Ph.D. then Associate Professor now Professor of Pharmaceutical Sciences, University of British Columbia (UBC)and President AK Analytical Services Dr. Axelson spent his sabbatical leave working in my laboratory. He was supported by UBC and a grant from the Canadian Heart Foundation; 1/80 to 12/80. 3. Klaus Stoeckel, Ph.D. was sent by and supported by Hoffmann-La Roche-Basle, Switzerland. Initially he intended to work with Dr. Milo Gibaldi, but because of Dr. Gibaldi's planned departure to accept the deanship at the University of Washington, Dr. Stoeckel spent 1/78 to 3/79 working in my laboratory. Dr. Stoeckel is now managing director of ClinPharm Support( Basel, Switzerland). 4. Patrick du Souich, M.D., Ph.D. moved from the University of Texas Health Sciences Center at San Antonio to Buffalo (supported as a Merck International Fellow in Clinical Pharmacology) when I moved. He worked in my laboratory but under the supervision of Dr. Gibaldi (until 5/78). After Dr. Gibaldi's departure to become Dean of School of Pharmacy at the University of Washington, Patrick spent 4 more months working in my laboratory. Dr. du Souich is now Professor and Chairman of Pharmacology at the University of Montreal. He worked in my lab from 7/77 to 10/78. 5. Allan J. McLean, M.D., Ph.D. also moved from the University of Texas Health Sciences Center at San Antonio to Buffalo (supported as a National Health/Medical Research Council fellow in Clinical Pharmacology by the government of Australia) when I moved. He also worked in my laboratory but under the supervision of Dr. Gibaldi until 5/78. Dr. McLean is now Professor, Department of Geriatric Medicine, Woden Valley Hospital/University of Sydney. He worked in my lab from 7/77 to 6/78. B. Post-doctoral Fellows 1. John Pieper, Pharm.D., worked as a post-doctoral fellow in my laboratory from 7/79 until 6/80. He left this fellowship position to accept an appointment as an Assistant Professor of Pharmacy Practice at the University of Florida. He is now Chairman, Department of Clinical Pharmacy, University of North Carolina. 2. David J. Edwards, Pharm.D., worked as a post-doctoral fellow in my laboratory from 7/81 until 6/83. He left this fellowship position to accept an appointment as an Assistant Professor of Pharmaceutical Sciences at Wayne State University. He is now a Professor at the same institution. 3. Craig K. Svensson, Pharm.D., Ph.D., worked as a post-doctoral fellow in my laboratory from 7/84 until 10/85. He left this fellowship position to accept an appointment as an Assistant Professor of Pharmaceutical Sciences at Wayne State University where he is now a Professor and Vice-Chairman. 4. James Baxter, Pharm.D. worked as a post-doctoral fellow in my laboratory from 7/84 until 9/85. He then decided to continue his education and completed his Ph.D. working in my laboratory (supported by an American Foundation for Pharmaceutical Education Fellowship). He is currently a senior research scientist at the Central Research Laboratory, Pfizer Inc. 5. Allan K.L. Wong, Ph.D. worked as a post-doctoral fellow in my laboratory from 2/86 unitl 9/87. He then joined Novartis in Summit, New Jersey. 6. Cornelia Weber, Ph.D. worked as a post-doctoral fellow in my laboratory from 2/88 until 12/88. She was supported by F. Hoffmann-La Roche Basle and returned to work in the pharmacokinetics group at Roche Basle 12/12/88, where she has remained. C. Graduate Students 1. Patrick McNamara, Ph.D. received his doctoral degree for work done in the laboratory of Dr. Milo Gibaldi form 9/75 to 5/78 and that completed between 5/78 to 10/79 in my laboratory. He left my laboratory to be a visiting scientist at Hoffmann-LaRoche-Basle, Switzerland and is now a Professor in the Department of Pharmaceutics, University of Kentucky. 2. Alfred Elvin, Ph.D. received has doctoral degree in October of 1981 for work done in my laboratory. He left my lab to become an Assistant Professor of Pharmaceutics at the University of Illinois Health Sciences Center at Chicago. He is presently Director, of Pharmacokinetics for Zenith- Goldline Division of IVAX Corporation. 3. Robert Lanc, M.S. received his Master's Degree for work done in my laboratory (1/82 to 3/86). He is now working in the Clinical Pharmacokinetics Laboratory at Millard Fillmore Hospital, Buffalo, NY. 4. Craig K. Svensson, Pharm.D., Ph.D. did both his graduate work and post-doctoral fellowship in my laboratory. He is described in post-doctoral fellows section. 5. Marlene Woodruff Modi, Ph.D. received her doctoral degree in November of 1987 for work done in my laboratory. She is now a Senior Research Scientist at Hoffmann-La Roche, Nutley, NJ. 7. Hsiao-Hui Chow, Ph.D. received her doctoral degree in May of 1989 for work done in my laboratory. She is now an Assistant Professor, Department of Pharmaceutical Sciences at the University of Arizona. 8. James Baxter, Pharm.D., Ph.D. received his Ph.D. degree in November 1989 for work done in my laboratory. He is presently a senior research scientist at the Central Research Laboratory, Pfizer Inc. 9. Shun-Wen Chang, Ph.D. received her doctoral degree in December of 1991 for work done in my laboratory (degree granted by SUNY/Buffalo for work done in my laboratories at SUNY/Buffalo and WVU). She is currently a senior research scientist at Novartis. 10. K. Gary Barnette, Ph.D. received his doctoral in May 1995 for work done in my laboratory. He is currently the Director of Regulatory Affairs for Solvay Pharmaceuticals(US). 11. Qinying Zhao received her Ph.D.done in my laboratory in February 1996. She is currently a Manager in the Clinical Pharmacokinetics Section of Janssen Pharmaceuticals (US). 12. Ping Li received her M.S. for work done in my laboratory in June 1996. She is currently a research scientist at Millenium Pharmaceuticals. 13. Carol Cronenberger received her Ph.D. for work done in my laboratory in July 1997. She is currently a senior scientist with Proctor and Gamble. E. Other Research Training Activities 1. In the 12 1/2 years I was in Buffalo, I served on approximately 10 Ph.D. committees (other than those of my own students); I have been a member of the Pharm.D. Research Committees for about 10 students and there have been about 10 undergraduate research students who have worked in my laboratory. F. Major (> 5 lectures per course listed) Teaching 1. At West Virginia University (a) Pharmacy 301 (Graduate Level Pharmacokinetics) Course Coordinator, presented 75-100% of lectures (3 credits) Spring 1991, 1993, 1995, 1997 and 1999
2. At the State University of New York at Buffalo
Bibliography A. Referred Articles 1. Lalka D and Back N: The high voltage paper electrophoresis of kinin peptides, K 9, K 10, and K 11. Biochim Biophys Acta 236:45-51 (1971). 2. Lalka D and Bardos TJ: Studies on the reactions of 2,2-dimethylaziridine-type alkylating agents in biological systems. I. Colorimetric estimation and stability in physiologic media. J Pharm Sci 62:1294-1298 (1973). 3. Lalka D and Feldman H: Absolute drug bioavailability: Approximation without comparison to a parenteral dose for compounds exhibiting perturbable renal clearance. J Pharm Sci 63:1812 (1974). 4. Lalka D and Bardos TJ: Cyclophosphamide, 2,2-dimethylaziridines, and other alkylating agents as inhibitors of serum cholinesterase. Biochem Pharmacol 24:455-462 (1975). 5. Lalka D, Jusko WJ and Bardos TJ: Reactions of 2,2-dimethylaziridine-type alkylating agents in biologic systems. II. A pharmacokinetic structure activity study in dogs. J Pharm Sci 64:230-235 (1975). 6. Lalka D, Meyer MB, Duce BR and Elvin AT: Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. Clin Pharmacol Ther 19:757-766 (1976). 7. Haegele KD, Skrdlant HB, Robie NW, Lalka D and McNay JL: Determination of hydralazine and its metabolites by gas chromatography-mass spectrometry. J Chromatog 126:517-534 (1976). 8. Manion CV, Lalka D, Baer DT and Meyer MB: Absorption kinetics of procainamide in man. J Pharm Sci 66:981-984 (1977). 9. Ludden TM, Allen JP, Valutsky WA, Vicuna AV, Nappi JHM, Hoffman SF, Wallace JE, Lalka D and McNay JL: Individualization of phenytoin dosage regimens. Clin Pharmacol Ther 21:287-293 (1977). 10. Ludden TM, Lalka D, Wyman MG, Goldreyer BN, Haegele KD, Brooks DT, Davila I and Wallace JE: Microdetermination of procainamide in human serum. J Pharm Sci 371-373 (1978). 11. Wyman MG, Lalka D, Hammersmith L and Goldreyer BN: Multiple bolus technique for lidocaine administration during the first hours of an acute myocardial infarction. Amer J Cardiol 41:313-317 (1978). 12. McLean AJ, McNamara PJ, du Souich P, Gibaldi M and Lalka D: Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin Pharmacol Ther 24:5-10 (1978). 13. Lalka D, du Souich P, McLean AJ and Gibaldi M: Absolute drug bioavailability II. Evaluation of the renal clearance perturbation method using literature data assuring a fraction absorbed of unity. J Pharm Sci 67:591-592 (1978). 14. Lalka D, Wyman MG, Goldreyer BN, Ludden TM and Cannon DS: Procainamide accumulation kinetics in the immediate post-myocardial infarction period. J Clin Pharmacol 18:397-401 (1978). 15. , Vicuna N, Burrow SR, Jones DJ, Ludden TM, Haegele KD and McNay JL: Bupivacaine and other amide local anesthetics as inhibitors of the hydrolysis of chloroprocaine by human serum. Anesth Analg 57:534-539 (1978). 17. du Souich P, McLean AJ, Lalka D, Vicuna N, Chauhuri E and McNay JL: Sulfadiazine handling in the rabbit II. Mechanism of nonlinear kinetics of elimination. J Pharmacol Exp Ther 207:228-235 (1978). 18. du Souich P, Lalka D, McLean AJ, Vicuna A and McNay JL: Comparison of screening methods for determination of N 4 -acetyltransferase capacity (acetylator phenotype) in outbred rabbit strains. J Lab Clin Med 92:290-296 (1978). 19. Taylor JW, McLean AJ, Leonard RG, Ludden TM, Clibon U, du Souich BP, Harris SC, Lalka D, Talbert RL, Vicuna N, Walton CA and McNay JL: Initial experience of clincial pharmacology and clinical pharmacy interactions in a clinical pharmacokinetics consultation service. J Clin Pharmacol 19:1-7 (1979). 20. Vicuna N, Lalka D, Burrow SR, McLean AJ, du Souich P and McNay JL: Dose-dependent pharmacokinetic behavior of lidocaine in the conscious dog. Res Commun Chem Pathol Pharmacol 22:485-491 (1978). 21. du Souich P, Lalka D, Slaughter R, Elvin AT and McLean AJ: Mechanisms of nonlinear disposition kinetics of sulfamethazine in normal volunteers. Clin Pharmacol Ther 25:172-183 (1979). 22. Elvin AT, Keenaghan JB, Byrnes EW, Tenthorey PA, McMaster PD, Takman BH, Lalka D, Manion CV, Baer DT, Wolshin EM, Meyer MB and Ronfeld RA: Conjugation of tocainide in man: A novel pathway of biotransformation for a primary amine. J Pharm Sci 69:47-49 (1980). 23. Stoeckel K, McNamara PJ, McLean AJ, du Souich P, Lalka D and Gibaldi M: Nonlinear pharmacokinetics of indocyanine green in the rabbit and rat. J Pharmacokin Biopharm 8:483-496 (1980). 24. McNamara PJ, Slaughter RL, Visco JP, Elwood CM, Siegel JH and Lalka D: Effect of smoking on the binding of lidocaine to human serum proteins. J Pharm Sci 69:749-751 (1980). 25. Wyman MG, Goldreyer BN, Cannom DS, Ludden TM and Lalka D: Factors influencing procainamide total body clearance in the immediate post-acute myocardial infarction period. J Clin Pharmacol 21:20-25 (1981). 26. Vicuna A, Lalka D, du Souich P, Vicuna N, Ludden TM and McLean AJ: Dose-dependence of the apparent half-life of phenytoin in the rat. Res Commun Chem Pathol Pharmacol 28:3-11 (1980). 27. Elvin AT, Lalka D, Stoeckel K, du Souich P, Axelson JE, Golden LH and McLean AJ: Pharmacokinetics and metabolism of tocainide in man: Effects of coadministration of phenobarbital and substrates for glucuronyl transferase. Clin Pharmacol Ther 28:652-658 (1980). 28. McNamara PJ, Slaughter RL, Pieper JA, Wyman MG and Lalka D: Factors influencing the serum protein binding of lidocaine in humans. Anesth Analg 60:395-400 (1981). 29. McNamara PJ, Lalka D and Gibaldi M: Endogenous accumulation products and serum protein binding in uremia. J Lab Clin Med 98:730-740 (1981). 30. Elvin AT, Cole AFD, Pieper JA, Rolbin SH and Lalka D: Effect of food on lidocaine kinetics: Mechanism of food-related alteration in high intrinsic clearance drug elimination. Clin Pharmacol Ther 30:455-460 (1981). 31. Edwards D, Lalka D, Cerra F and Slaughter RL: Alpha 1 -acid glycoprotein concentration and protein binding in trauma. Clin Pharmacol Ther 31:62-67 (1982). 32. Gipple KJ, Chan KT, Elvin AT, Lalka D and Axelson JE: Species differences in the urinary excretion of the novel primary amine conjugate: Tocainide carbamyl-O- b-D-glucuronide. J Pharm Sci 71:1011-1014 (1982). 33. Elvin AT, Axelson JE and Lalka D. Tocainide binding in normal volunteers and trauma patients. Brit J Clin Pharmacol 13:872-874 (1982). 34. Svensson CK, Edwards DJ, Lalka D, Mauriello PM, and Middleton EM: Comparison of chromatographic and spectrophotometric analysis of indocyanine green in plasma following administration of multiple doses to man. J Pharm Sci 71:1305-1306 (1982). 35. Svensson CK, Edwards DJ, Mauriello PM, Barde SH, Foster AC, Lanc RA, Middleton E and Lalka D: Time course of the effect of food on hepatic blood flow: Implications in the "Food Effect" phenomenon. Clin Pharmacol Ther 34:316-323 (1983). 36. Wyman MG, Slaughter RL, Farolino DA, Gore S, Cannom DS, Goldreyer BN and Lalka D: Multiple bolus technique for lidocaine adminstration II. Treatment of refractory ventricular arrhythmias and the pharmacokinetic significance of severe left ventricular failure. J Am Coll Cardiol 2:764-769 (1983). 37. Hardy BG, Zador IT, Golden L, Lalka D and Schentag JJ: Effect of cimetidine on the pharmacokinetics and pharmacodynamics of quinidine. Am J Cardiol 52:172-175 (1983). 38. Goolkasian DL, Slaughter RL, Edwards DJ and Lalka D: Displacement of lidocaine from serum alpha 1-acid glycoprotein binding sites by basic drugs. Europ J Clin Pharmacol 25:413-417 (1983). 39. Svensson CK, Mauriello PM, Barde SH, Middleton E and Lalka D: Effect of carbohydrate on estimated hepatic blood flow. Clin Pharmacol Ther 35:660-665 (1984). 40. Kapil RP, Abbott FS, Kerr CR, Edwards DJ, Lalka D and Axelson JE: Simultaneous quanititation of disopyramide and its mono-dealkylated metabolite in human plasma by fused-silica capillary gas chromatography using nitrogen-phosphorus specific detection. J Chromatog 307:305-321 (1984). 41. Kung MP, Ho YK, Lalka D and Bardos TJ: Pharmacokinetic and metabolic studies of partially thiolated polycytidylic acid in rodents. Cancer Res 44:4602-4606 (1984). 42. Anderson GD, Elvin AT and Lalka D: Estimation of tris (butoxyethyl) phosphate in biological fluids: Novel inter-subject variability in its recovery from human serum. J Pharm Sci 73:1791-1793 (1984). 43. Edwards DJ, Axelson JE, Slaughter RL, Elvin AT and Lalka D: Factors affecting quinidine protein binding in man. J Pharm Sci 73:1264-1267 (1984). 44. Svensson CK, Cumella JC, Tronolone M, Middleton E and Lalka D: Effect of hydralazine, nitroglycerin and food on estimated hepatic blood flow. Clin Pharmacol Ther 37:464-468 (1985). 45. Kapil RP, Axelson JE, Lalka D, Edwards DJ and Kerr CR: Application of capillary gas liquid chromatography to the measurement of free fraction of disopyramide in human plasma. Res Commun Chem Path Pharmacol 48:153-156 (1985). 46. Kirkwood CF, Edwards DJ, Lalka D, Lasezkay GM, Hassett JM and Slaughter RL: The pharmacokinetics of meperidine in acute trauma patients. J Trauma 26:1090-1093 (1986). 47. Heintz R, Svensson CK, Stoeckel K, Powers GJ and Lalka D: Indocyanine green: Pharmacokinetics in the rabbit and relevant studies of its stability and purity. J Pharm Sci 75:398-402 (1986). 48. Edwards DJ, Axelson JE, Visco JP, van Every S, Slaughter RL and Lalka D: Lack of effect of smoking on the metabolism and pharmacokinetics of quinidine in patients. Brit J Clin Pharmacol 23:351-354 (1987). 49. Kapil RP, Axelson JE, Mansfield IL, Edwards DJ, McErlane B, Mason MA, Lalka D and Kerr CR: Disopyramide pharmacokinetics and metabolism: Effect of Inducers. Brit J Clin Pharmacol 24:781-791 (1987). 50. Hassett JM, Doolittle T, Molloy M and Lalka D: Reaction to anticonvulsants following head injury. NYS J Med 129:571-573 (1987). 51. Woodruff-Modi M, Hassett JM and Lalka D: Influence of posture on hepatic perfusion and the presystemic biotranformation of propranolol: Simulation of the food effect. Clin Pharmacol Ther 44:268-274 (1988). 52. Edwards DJ, Lalka D, Slaughter RL and Hassett JM: The differing effect of pentobarbital and chloralose in anesthetic doses on the serum protein binding of lidocaine in the dog. J Pharm Sci 77:466-467 (1988). 53. Kelley K, Price RM, Baxter JG, Steinberg S, Lalka D and Hassett JM. In vivo macrophage activation alters hepatocyte metabolism. Surg Forum, 39:4-5 (1988). 54. Shuster D, Woodruff-Modi M, Lalka D and Gengo F. A reverse phase HPLC assay to resolve metoprolol enantiomers in plasma. J Chromatog, 433:318-325 (1988). 55. Barnett JA, Brenner DE, Creaven PJ and Lalka D: Lack of effect of treatment with human recombinant-tumor necrosis factor (HrTNF) on the binding of drugs to a 1-acid glycoprotein (AGP). Brit J Clin Pharmacol, 27:257-261 (1989). 56. Steinberg S, Flynn W, Kelley K, Bitzer L, Sharma P, Gutierrez C, Baxter J, Lalka D, Sands A, Van Kiew J, Hassett J, Price R, Beam T and Flint L: Development of a bacteria-independent model of the multiple organ failure syndrome. Arch Surg 124:1390-1395 (1989). 57. Chow H. -H. and Lalka D: The influence of vitamin K 3 treatment on the pharmacokinetics and metabolism on d-propranolol in the rat. Drug Metab Dispos, 20:288-204 (1992). 58. Chow H -H and Lalka D: Pharmacokinetics of d-propranolol following oral and intraportal administration: Contrasting effects of oral glucose. Biopharm Drug Dispos, 14:217-231 (1993). 59. Weber C, Stockel K, and Lalka D: Accumulation kinetics of propranolol in the rat: Comparison of Michaelis Menten mediated clearance and clearance changes consistent with the "Altered Enzyme Hypothesis". Pharm Res. 11:420-425 (1994). 60. Glover DD, Lalka D and Monif GRG: Ampicillin vs Penicillin for in utero therapy. Infect Diseases Obstet Gynecol 4: 43- 46,1996. 61. Barnette KG, Sarkar MA, Glover DD, Li P, Boyd C and Lalka D: Glutathione S-transferase in human endometium:Quantition and Interindividual Variability in Isoform Content. Gynecol Obstet Invest 47: 114-119, 1999. 62. Kovacs P, Edwards DJ, Lalka D, Scheiwe MW and StoeckelK:High dose omeprazole: Use of a multiple-dose study design to assess bioequivalence and accuracy of 2C19 phenotyping. Therap Drug Monit 21: 526-531,1999. B. Invited Reviews, Book Chapters and Proceedings of Meetings 1. du Souich P, McLean AJ, Lalka D, Erill S and Gibaldi M: Pulmonary disease and drug kinetics, Clin Pharmacokin 3:257-266 (1978). 2. Green L, Wyman MG and Lalka D: Clinical pharmacokinetics of lidocaine: A counterpoint discussion, pp 392-403, in Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, edited by WE Evans, JJ Schentag and WJ Jusko, Applied Therapeutics, Inc., San Francisco, CA (1980). 3. Pieper J, Slaughter RL, Anderson G, Wyman MG and Lalka D: Clinical pharmacokinetics of lidocaine, Drug Intell Clin Pharm, 16:291-294 (1982). 4. Edwards DJ, Svensson CK, Visco JP and Lalka D: Clinical pharmacokinetics of pethidine (meperidine). Clin Pharmacokin 7:421-244 (1982). 5. du Souich P, McLean AJ, Lalka D, Erill S and Gibaldi M: Pulmonary disease and drug kinetics, in the Handbook of Clinical Pharmacokinetics, edited by Gibaldi M and Prescott L, ADIS Health Science Press, New York, NY pp III 201-211 (1983); original article cited as #1 in this section was essentially reprinted in this book. 6. McLean AJ, Lalka D, Corcoran GB and Melander A: Drug-Nutrition Interactions, pp 1-8, in Wahlquist, John Libbey, London and Paris (1986). 7. Svensson CK, Woodruff MN, Baxter JG and Lalka D: Free drug level monitoring in clinical practice: Rationale and current status. Clin Pharmacokin 11:450-469 (1986). 8. Svensson CK, Woodruff MN and Lalka D: Influence of protein binding and use of unbound (free) drug concentration, pp. 187-219, in Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Second Edition, edited by WE Evans, JJ Schentag and WJ Jusko, Applied Therapeutics, Spokane (1986). 9. Koup JR and Lalka D: Principles of Therapeutics, pp. 617-635 in Allergy: Principles and Practice, 3rd Edition, edited by E. Middleton, C.E. Reed, E.F. Ellis, N.F. Adkinson and J.W. Yunginger, C.V. Mosby Co., St. Louis, MO., (1988). 10. Melander A, Lalka D and McLean AJ: Influence of food on the presystemic metabolism of drugs. Pharmacol Ther 38:253-267 (1988). (At the request of the editor, this review was also reproduced in the International Encyclopedia of Pharmacology and Therapeutics.) 11. Melander A, Lalka D and McLean A: Food and drug bioavailability, pp. 195-203 in Recent Advances in Clinical Nutrition III, edited by AJ McLean and M Wahlquist, John Libbey, London and Paris, (1988). 12. Baxter JG, Barnett JA and Lalka D: Pharmacokinetic Modulation of the Dose-Response relationship. Excerpta Media International Congress Series, edited by L Lasagna, C Naranjo and S Erill, Elsevier Science Publishers, Amsterdam, pp. 49-64 (1989). 13. Cole, AFD, Baxter JG, Jackson BJ, Hew-Wing P, Guentert TW and Lalka D: Pharmacokinetics and Metabolic Aspects of the Moclobemide - Food Interaction. Psychopharmacology, 106: S37-S39 (1992). 14. Stout PJ, Sarkar MA and Lalka D: Pharmacokinetic/Pharmacodynamic Modelling of Analgesic Effect. Rheumatology News and Trends/Supplement 1:14-16 (1991). 15. Lalka D, Griffith R and Cronenberger CL: The hepatic first pass metabolism of problematic drugs. J. Clin Pharmacol., 33:657-669 (1993). 16. Du Souich P and Lalka D, editors: Pharmacokinetics: Development of an Exquisitely Practical Science, ISBN: 84-8124-159-9, Prous Science , Barcelona and Philadelphia (1999). C. Invited Seminars/Presentations at National Meetings Since 1983 1. Effect of food consumption on hepatic perfusion and the elimination of high clearance drugs. Presented to the School of Pharmacy, University of Washington, Seattle, March 14, 1983. 2. Effect of food consumption on hepatic perfusion and the elimination of high clearance drugs. Presented to the faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, B.C., March 15, 1983. 3. Indocyanine green pharmacokinetics and chemical stability. Presented at the Eastern Section, American Federation for Clinical Research, Cambridge MA, October 14, 1983. 4. Physiologic effects of food on hepatic perfusion and on the activity of drug metabolizing enzymes: Implications for Oral Drug Bioavailability. Presented at the Sixth Annual Eino Nelson Memorial Conference, Paradise Island Hotel, Nassau, Bahamas, December 6, 1983. 5. The effect of food on hepatic perfusion and hepatic clearance: Implications for oral drug bioavailability. Presented at the 3rd Biennial Buffalo Pharmaceutics Symposium, July 28, 1984. 6. Food, splanchnic blood flow and the first-pass metabolism of high clearance drugs: Studies in man and preliminary data in the dog. Presented to the Departments of Biochemical Pharmacology and Pharmacology and Therapeutics, SUNY/Buffaclo, December 5, 1984. 7. Food, splanchnic blood flow and the first-pass metabolism of high clearance drugs. Presented to F. Hoffmann-La Roche & Co., Ltd., Basle, Switzerland, May 22, 1985. 8. Food, splanchnic blood flow and the first-pass metabolism of high clearance drugs. Presented at the Pharmacology and Therapeutics Department, University of Sheffield, Sheffield, England, May 28, 1985. 9. The effect of food consumption on hepatic perfusion and the elimination of high clearance drugs. Presented to the Department of Anaesthesia and Intensive Care, Flinders University Medical Center, Adelaide, Australia, September 24, 1985. 10. The effect of food consumption on hepatic perfusion and the elimination of high clearance drugs. Presented to the Drug Delivery Systems Section, Eastman Kodak Company, Rochester, NY, April 8, 1986. 11. The effect of food consumption on hepatic perfusion and the elimination of high clearance drugs. Presented to the University of Toronto, Clinical Pharmacology Division, Toronto, Ontario, April 22, 1986. 12. The effect of food consumption on hepatic perfusion and the elimination of high clearance drugs. Presented to the Bureau of Drug Research, Health Protection Branch, Ottawa, Ontario, April 30, 1986. 13. The effect of food consumption on hepatic perfusion and the elimination of high clearance drugs. Presented to the Department of Pharmaceutical Sciences of Wayne State University, Detroit, MI, December 1, 1986. 14. The effect of food consumption on hepatic perfusion and the elimination of high clearance drugs. Presented to the School of Pharmacy, West Virginia University, Morgantown, WV, March 10, 1987. 15. Food Consumption: Effect on factors controlling hepatic first-pass metabolism. Presented to the Pharmacokinetics Section, Medical Department, F. Hoffmann-La Roche & Co., Ltd., Basle, Switzerland, April 11, 1987. 16. Food Consumption: Effect on factors controlling hepatic first-pass metabolism. Presented to the Division of Clinical Pharmacology, University of Lund, Lund, Sweden, April 17, 1987. 17. Food Consumption: Effect on factors controlling hepatic first-pass metabolism, to the Faculty of Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, March 14, 1988. 18. Pharmacokinetic modution of the dose-response relationship. Presented at the Esteve Foundation Symposium III. Mallorca, Spain, October 13, 1988. 19. Barnett JA and Lalka D: Effect of turpentine-induced inflammation on serum protein binding and hepatic metabolism of model drugs. Poster presentation at the American Association of Pharmaceutical Scientists Meeting in Orlando, Florida, November 1, 1988. 20. Chow H-H and Lalka D: Effect of vitamin K 3 on propranolol disposition in the rat. Poster presentation at the American Association of Pharmaceutical Scientists Meeting in Orlando, Florida, November 1, 1988. 21. Lipophilic basic drugs: A search for an understanding of their aclassical disposition. Presented at West Virginia University, School of Pharmacy, Morgantown, WV, February 20, 1989. 22. Lipophilic basic drugs: A search for an understanding of their aclassical disposition. Presented at the National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, April 17, 1989. 23. Food consumption: Effect on factors controlling hepatic first-pass metabolism. Presented to the College of Pharmacy, University of Arizona, Tucson, AZ, April 28, 1989. 24. "Pharmacokinetic modulation of the dose-response relationship". Presented to the Canadian Society for Clinical Investigation/Canadian Society for Clinical Pharmacology, 59th Annual Meeting, Toronto, Canada, September 16, 1990 (also serves as Section Chairman). 25. "Acute and Chronic Drug-Nutrition Interactions" to the 4th Interamerican Congress of Clinical Pharmacology and Therapeutics. Mexico City, Mexico, September 20, 1990. 26. "Pharmacokinetic/Pharmacodynamic modelling of Analgesic effect" to the 13th European Congress of Rheumatology. Budapest, Hungary, July 1, 1991. 27. Lipophilic Basic Drugs: A search for an understanding of their aclassical disposition. Presented to the Clinical Pharmacokinetics Section of Glaxo, Inc. Research Triangle Park, NC, February 19, 1992. 28. The hepatic first pass metabolism of problematic drugs. Presented at the 21st annual meeting of the American College of Clinical Pharmacology, Washington, DC, September 18, 1992. 29. Chang SW and Lalka D: Influence of chlorpromazine on the pharmacokinetics and metabolism of d-propranolol in rats. Poster presentation at the American Association of Pharmaceutical Scientists Meeting in San Antonio, Texas, November 17, 1992. 30. Barnette KG, Lalka D, Boyd CB, Glover DD and Sarkar MA: Characterization of Toxicologically significant enzymes in human reproductive tissue: Cytochrome P-450IA1 activity in human uterus. Poster presentation at the American Association of Pharmaceutical Scientists Meeting in San Antonio, Texas, November 17, 1992. 31. " Non-stationary First Pass Hepatic Metabolism: Hypotheses to Explain Observations in Man and Mechanistic Evaluation in the Rat." Presented to the Department of Pharmacology, University of Montreal, Montreal, Canada, February 12, 1993. 32. Barnette KG, Glover DD, Boyd CB, Lalka D and Sarkar MA: "Polycyclic aromatic hydrocarbon (PAH) inducable P450 isozymes (1A1 and 1A2) and glutathione-S-transferous (GST) activity in human uterine tissue - Poster presentation at the American Federation for Clinical Research in Washington, DC, April 30, 1993. 33. Zhao Q-Y, Stoeckel K and Lalka D: Uranyl nitrate induced renal failure in rats yields clearance changes analogous to renal failure in man: Studies with ceftriaxone. Poster presentation at the Eighth Annual Meeting of the American Association of Pharmaceutical Scientists in Orlanda, Florida, November 18, 1993. 34. Slain D, Amsden JR, Khakoo RA, Fisher MA, Lalka D and Hobbs GR: Effect of High-Dose Vitamin C on the Steady-State Pharmacokinetics of the Protease Inhibitor Indinavir in Health Volunteers(to be presented at the 43 rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ( Chicago, Sept 14-17,2003). 35. Gutierrez G, Lalka D, Garrett IR, McCluskey B, Rossini G, Fourquet RE, Rivas and Mundy GR: New Formulation for Transdermal Delivery of Lovastatin (to be presented at the 25 th Annual Meeting of the American Society for Bone and Mineral Research (Minneapolis, Sept 19-23,2003).
GRANTS AND CONTRACTS FUNDED
1. General Research Support Grant 5 S01 RR 05654-06 from General Research Support Branch, Division of Research Facilities and Resources, NIH, 12/1/75 to 12/31/77. The relationship between acute diphenylhydantoin intoxication and the concentration of free drug and total drug in the plasma of rats. ($3,970 first year, $7,970 total); D. Lalka, principal investigator, awarded to UTHSCSA. 2. American Heart Association, Texas Affiliate, 7/1/76 to 6/30/77 . Dose-Dependent Pharmacokinetic Behavior of Lidocaine. ($9,500 total); D. Lalka, principal investigator, awarded to UTHSCSA. 3. Astra Pharmaceutical Products, Inc., unrestricted support for use in education of health professionals with regard to the proper use of antiarrhythmic drugs ( 2/1/76 until funds exhausted, $2,000); D. Lalka, principal investigator, awarded to UTHSCSA. 4. E.R. Squibb and Sons, Procainamide Multiple Bolus and Continuous Infusion Study in Acute Myocardial Infarction Patients. ( 11/12/76 - until funds are exhausted, $9,800); D. Lalka, principal investigator, awarded to UTHSCSA; funds moved to SUNY/Buffalo. 5. Research Grant 1 RO1 GM23734, Metabolism and Pharmacokinetics of Amphotericin B ( 6/25/76 - 6/30/79); D. Lalka, co-investigator $44,000 first year, $141,000 total); awarded to UTHSCSA. 6. Center Grant 2P50 GM 20852: The Pharmacokinetics of Lidocaine and its Dealkylated Metabolites in Acute Myocardial Infarction and Coronary Artery Bypass Patients; funded by NIGMS, $26,000 first year, $108,000 total. This was my component of the Department of Pharmaceutics Center Grant, awarded to SUNY/Buffalo ( 1/1/79 to 12/31/83 ). 7. Influence of Enzyme Inducing Drugs and Substrates for the Glucuronyl Transferase Enzyme System Upon the Pharmacokinetics of Tocainide, Astra Pharmaceuticals, Inc., $8,800, 2/1/78 until funds exhausted, D. Lalka, principal investigator, awarded to SUNY/Buffalo. 8. Simultaneous Quantitative Analysis of Lidocaine and its Pharmacologically Active Metabolites; Biomedical Research support Grant, SUNY/Buffalo, $2,100, 7/1/78 - 6/30/79, D. Lalka, principal investigator. 9. Pharmacokinetics of Sustained Release Theophylline Preparations, Rorer, Inc. $41,729, 12/1/78 until funds exhaused, D. Lalka, co-investigator. ($10,000) subcontracted to me at SUNY/Buffalo. 10. Tocainide Pharmacokinetics in Humans, from the British Columbia Heart Foundation, James Axelson, principal investigator, 7/1/79 - 6/10/81 , $16,619 subcontracted to D. Lalka at SUNY/Buffalo. 11. Performance of a Programmable Lidocaine Infusion Pump. Cardiac Pacemakers, Inc., $11,987, 5/7/82 - 12/31/83, D. Lalka, principal investigator. 12. Amiodarone Pharmacokinetics in Coronary Care Unit Patients. San Pedro Peninsula Hospital Foundation ( San Pedro, CA), 1/27/83 - 6/30/85, $13,500, D. Lalka, principal investigator. 13. Quinidine Pharmacokinetics and Metabolism in Man: Enzyme Inductive Effects of Cigarette Smoking and Phenobarbial; Effect of Disease States on Plasma Protein Binding. James Axelson, principal investigator, from the British Columbia Heart Foundation, $17,711, subcontracted to D. Lalka SUNY/Buffalo. 14. Disopyramide Pharmacokinetics: Concentraction-Effect Relationship; Role of -Acid Glycoprotein in Serum Protein Binding; and the Enzyme Inductive Effects of Cigarette Smoke and Phenobarbital; from the Canadian Heart Foundations (British Columbia Affiliate); James Axelson, prinicipal investigator, 7/1/83 - 6/30/86; $6,000 subcontracted to D. Lalka SUNY/Buffalo. 15. Center Grant 2P 50 GM20852: Effect of Food on Drug Disposition was my component of the Department of Pharmaceutics, Pharmacology/Toxicology Center Grant, total of $279,178 was awarded to me for the period 1/1/84 - 6/31/89. 16. The Effect of Concurrent Drug Administration and Food Consumption on Steady State Metoprolol Plasma Concentration, $8,800, 10/1/82 - 9/30/83 ( Astra Pharma, Canada); D. Lalka, prinicipal investigator. 17. The Effect of Concurrent Drug Administration and Food Consumption on Steady State Metoprolol Serum Levels Following the Administration of Sustained Release Metroprolol Tablets. I. (Astra Pharma), D. Lalka, principal investigator; $22,330 ( 11/4/84 - 7/1/87). 18. The Effect of Concurrent Drug Administration and Food Consumption on Steady State Metoprolol Serum Levels Following the Administration of Sustained Release Metoprolol Tablets. II. (Astra Pharma), D. Lalka, principal investigator; $31,500 ( 7/1/87 - 6/30/88). 19. Studies to Identify an Appropriate Animal Model of Human Congestive Heart Failure: The Pharmacokinetics of Selected Drugs and Cibenzoline in a Biventricular Failure Model from F. Hoffmann-LaRoche & Co., ( Nutley), D. Lalka, co-principal investigator, ( 5/1/85 - until funds exhausted), $23,670. 20. Metabolic and Pharmacokinetic Interaction of Moclobemide with Food: Assessment of Underlying Mechanisms in Man, from F. Hoffmann-LaRoche & Co., Basle, ( 1/23/88 - until funds exhausted) $39,637, D. Lalka, principal investigator. 21. Moclobemide Disposition in the Rat: Effect of Chronic Administration on its own Pharmacokinetics and Hepatic Microsomal Metabolism of Model Substrates. (F. Hoffmann-LaRoche & Co., Basle), D. Lalka, principal investigator; $47,200, 11/1/87 - until funds exhausted. 22. Antineoplastic Drug Hepatic Interactions in a Rabbit Model. (National Cancer Institute), D. Lalka, consultant and subcontractor, Dean E. Brenner, principal investigator; 1R01 CA44621. $83,789 first year ($264,754 total), 12/1/87 - 11/30/90. 5% effort. Subcontract of approximately $10,000 23. Studies to Explore the Cause of Interindividual Variability in the Non-Renal (Biliary) Clearance of Ceftriaxone in Man: I. Development of an Appropriate Animal Model and its Evaluation in the Presence of Renal Failure (from F. Hoffmann-LaRoche & Co., Basle, $40,000 received 12/1/88 and an additional $22,734 received 12/20/93) D. Lalka, principal investigator. 24. The Pharmacokinetic Interactions of Propranolol and Chlorpromazine (from Hoffmann-LaRoche Inc. ( Nutley, N.J.) $5,000 (1/89 until funds exhausted) D. Lalka, principal investigator. 25. Evaluation of human and rat liver microsomal models to predict the in vivo potency of quinolones as inhibitors of theophylline metabolism in man; from Warner Lambert Co. ( Morris Plains, N.J.) $20,000. D. Lalka - co-principal investigator (11/90 - 6/94). 26. Metabolic and Pharmacokinetic Interaction of Moclobemide with Food: Assessment of Underlying Mechanisms in Man, (Phase II) from F. Hoffmann-LaRoche & Co., ( Basle, 1/23/88 -until funds exhausted $39,637). Original Award. A supplemental budget of $30,518 was awarded 6/1/91 to expand this study. D. Lalka - principal investigator. 27. "Role of P450 and Detoxification Enzymes in Uterine Cancer" from the National Cancer Institute (R29CA62369) 8/1/94 - 6/30/99. $349,749 (direct costs) M.A. Sarkar Principal Investigator; D. Lalka 20% effort as a collaborator. Awards for Training in my Lab (Direct Financial Awards to the Institution or its Affiliated Foundation) 1. Fellowship support for Cornelia S. Weber, Ph.D. to train in my laboratory from 2/88 to 12/88 ($44,500 total from F. Hoffmann-LaRoche Basle Switzerland). 2. Fellowship Award for Salvinaz H. Parpia Pharm.D. to train in my laboratory from the Medical Research Council of Canada (C$ 25,390 per year 9/1/88 to 12/31/89 awarded. 3. Fellowship Award for Grace Chan, Ph.D. from the Canadian Heart Foundation (C$22,900/year) 7/1/89 to 6/30/91. This award was returned unspent to the Canadian Heart Foundation because the Immigration and Naturalization Service denied Dr. Chan entry into the United States. 4. Other Fellowships/Studentships which students received to work in my laboratory but for which I was not their designated adviser on the application (i.e. I did not significantly participate in the preparation of the application for extra mural funding) are listed on pages 5 and 6 (eg. Janice Barnett and James Baxter received American Foundation for Pharmaceutical Education Fellowships). |
||